| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Medicine (A.K., A.M., M.L.), University of Kuopio, 70210 Kuopio, Finland; National Public Health Institute (J.G.E.), Department of Epidemiology and Health Promotion, 00300 Helsinki, Finland; Department of Public Health (T.F.), University of Helsinki, 00300 Helsinki, Finland; and MRC Environmental Epidemiology Unit (C.O., D.J.P.B.), University of Southampton, Southampton General Hospital, 5016 6YD Southampton, United Kingdom
Address all correspondence and requests for reprints to: Markku Laakso, Professor and Chair, Department of Medicine, University of Kuopio, 70210 Kuopio, Finland. E-mail: markku.laakso{at}kuh.fi.
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
2 gene on insulin sensitivity is modified by size at birth (8). Plasma cell glycoprotein 1 (PC-1, ENPP1) is a promising candidate gene for type 2 diabetes because it inhibits autophosphorylation of insulin receptor (IR) (9) and impairs insulin signaling downstream of IR (10). PC-1 has been shown to interact directly with IR (9), and the 121Q variant (Gln121) in exon 4 has a greater inhibitory action on IR than does the 121K allele variant (Lys121) (11). Additionally, PC-1 has enzymatic activity, and it plays a role in the regulation of signaling by nucleotides (12). Moreover, the K121Q genotype has been shown to be associated with insulin resistance (13) and high glucose and insulin levels (14). No data are available on the association of the PC-1 gene polymorphism with intrauterine growth. Therefore, the aim of our study was to investigate whether the impact of the K121Q polymorphism of the PC-1 gene on insulin sensitivity, and the occurrence of diabetes and hypertension, depends on size at birth.
| Subjects and Methods |
|---|
|
|
|---|
The original epidemiological study of 7086 men and women, born as singletons at the Helsinki University Hospital during 19241933, has been previously described (5). A total of 647 subjects from the original cohort were invited to attend a clinical study after an overnight fast (15). DNA samples were available for 489 subjects [180 men and 309 women; mean age 70 ± 3 yr; mean body mass index (BMI) 26.5 ± 4.0 kg/m2] of the 500 participants who came to the clinic. Altogether, 94 subjects were either taking medication for type 2 diabetes or were diagnosed at the clinic, 209 were taking medication for hypertension, and 56 of them were taking medication for both.
An oral glucose tolerance test was performed with glucose and insulin measurements at baseline (0 min) and at 120 min after a 75-g glucose load. Plasma glucose was measured by a hexokinase method and insulin, proinsulin, and 3233 split proinsulin were measured by two-site immunometric assay (16). The homeostasis model assessment for insulin resistance (HOMA-IR) was calculated using the following formula: fasting plasma glucose (mmol/liter) x fasting serum insulin (mU/liter)/22.5 (17). Serum lipid and lipoprotein concentrations were determined using standard methods.
Genotyping
Exon 4 of the PC-1 gene was amplified with PCR with a forward primer 5'-CTGTGTTCACTTTGGACATGTTG-3' and a reverse primer 5'-GACGTTGGAAGATACCAGGTTG-3' (13). The reaction was performed in a total volume of 20 µl containing 50 ng of genomic DNA, primers (0.5 µmol/µl), 0.375 U DNA polymerase (DynaZyme, Finnzymes, Espoo, Finland), and 100 µmol/liter deoxynucleotide triphosphate. PCR conditions were denaturation at 94 C for 4 min followed by 35 cycles of denaturation at 94 C for 40 sec, annealing at 62 C for 40 sec, and extension at 72 C for 40 sec with a final extension at 72 C for 4 min. The K121Q polymorphism was screened by the Eco47I restriction enzyme followed by polyacrylamide gel electrophoresis of the digested PCR products.
Statistical analysis
Data were analyzed with the SPSS/Windows program (version 10.0, SPSS Inc., Chicago, IL). Results are given as means ± SD unless differently indicated. Multiple linear regression was applied to compare the effect of the polymorphism on continuous variables after adjustment for age, sex, and current BMI. Plasma glucose, insulin, proinsulin, high-density lipoprotein cholesterol, and triglyceride values were log transformed before statistical analyses to achieve a normal distribution. Comparisons were made within length categories and within genotypes.
| Results |
|---|
|
|
|---|
Subjects carrying the 121Q allele had lower ponderal index compared with subjects who had the K121K genotype, but there were no differences in birth weight and length (Table 1
). BMI, systolic and diastolic blood pressures, and lipids and lipoproteins did not differ between subjects with the K121K genotype and those with the 121Q allele. Fasting glucose, 2-h glucose, insulin, and HOMA-IR did not differ between subjects with the K121K genotype and with the 121Q allele in the whole study group. The effect of the PC-1 gene polymorphism on insulin sensitivity, measured as fasting insulin levels or HOMA-IR, depended on birth length when subjects were divided into five length categories (P for interaction = 0.04 and 0.05, Table 2
). Fasting insulin levels and HOMA-IR were highest in subjects carrying the 121Q allele who were small at birth. In subjects with normal size, there was no effect of the 121Q allele on insulin sensitivity.
|
|
|
|
| Discussion |
|---|
|
|
|---|
In our study, size at birth was related to markers of insulin resistance, such as 2-h plasma insulin level, fasting proinsulin, 3233 split proinsulin, and HOMA-IR. We found an association of the 121Q allele with low ponderal index score, although there was no difference in birth length. This may suggest that PC-1 regulates intrauterine weight gain, as was previously shown for IGF-1 and glucokinase genes (18, 19). Subjects with the 121Q allele of the PC-1 gene can have altered response to insulin during fetal growth, resulting in decreased fetal weight gain. Insulin is an important growth determinant (6, 20, 21), especially in the third trimester, when fetal weight increases substantially. Thus, insulin sensitivity can be crucial for normal growth because subjects carrying risk genotypes, including the 121Q allele of the PC-1 gene, may be poorly adapted to undernutrition. PC-1 may affect insulin action also at the postreceptor site, but no influence of PC-1 on DNA synthesis has been found (10). Birth length may be also determined by other genes, which regulate fetal response to undernutrition and oxygen supply. Therefore, the interaction of the PC-1 gene with birth length may reflect interaction with environment or with other genes.
Subjects who had the 121Q allele of the PC-1 gene and who were short at birth were both hyperinsulinemic and insulin-resistant. They also had the highest prevalence of diabetes combined with hypertension. The prevalence of hypertension in patients with type 2 diabetes is around 60%, which is about 1.52 times higher than in the general population (22, 23). The causes for elevated blood pressure in patients with type 2 diabetes are unknown, but elevated blood pressure is often associated with hyperinsulinemia and insulin resistance (24, 25).
We found that the association of the 121Q allele with type 2 diabetes and hypertension was restricted to subjects who had impaired fetal growth, suggesting an interaction with environmental (for example, nutrition and oxygen supply) and genetic factors affecting intrauterine growth. The association of the PC-1 gene polymorphism with hypertension has not been previously reported. One possible mechanism explaining this association is insulin resistance. Indeed, the most insulin-resistant subjects in our study were subjects with the 121Q allele who were short at birth. These subjects also developed diabetes and hypertension (Fig. 2
). Moreover, in this group, the prevalence of hypertension in subjects with diabetes was higher than in patients with diabetes in general. In hypertensive patients, insulin resistance is found mainly in skeletal muscle (26) where the PC-1 gene is expressed. However, it is also possible that the enzymatic role of PC-1 in regulating signaling by nucleotides through purinergic receptors may be important because they play a role in the development of hypertension (27, 28).
We conclude that there is an interaction between the K121Q polymorphism of the PC-1 gene and intrauterine environment. This interaction affects insulin sensitivity and increases susceptibility to type 2 diabetes and its association with hypertension.
| Footnotes |
|---|
Abbreviations: BMI, Body mass index; HOMA-IR, homeostasis model assessment for insulin resistance; IR, insulin receptor; PC-1, plasma cell glycoprotein 1.
Received August 4, 2003.
Accepted January 23, 2004.
| References |
|---|
|
|
|---|
2 gene on insulin sensitivity and insulin metabolism interact with size at birth. Diabetes 51:23212324
-subunit. Diabetes 49:1319[Abstract]
This article has been cited by other articles:
![]() |
I. D. Goldfine, B. A. Maddux, J. F. Youngren, G. Reaven, D. Accili, V. Trischitta, R. Vigneri, and L. Frittitta The Role of Membrane Glycoprotein Plasma Cell Antigen 1/Ectonucleotide Pyrophosphatase Phosphodiesterase 1 in the Pathogenesis of Insulin Resistance and Related Abnormalities Endocr. Rev., February 1, 2008; 29(1): 62 - 75. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Nath, V. S. Voruganti, N. H. Arar, F. Thameem, J. C. Lopez-Alvarenga, R. Bauer, J. Blangero, J. W. MacCluer, A. G. Comuzzie, and H. E. Abboud Genome Scan for Determinants of Serum Uric Acid Variability J. Am. Soc. Nephrol., December 1, 2007; 18(12): 3156 - 3163. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Eriksson Gene Polymorphisms, Size at Birth, and the Development of Hypertension and Type 2 Diabetes J. Nutr., April 1, 2007; 137(4): 1063 - 1065. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Lebenthal and D. M. Bier Novel Concepts in the Developmental Origins of Adult Health and Disease J. Nutr., April 1, 2007; 137(4): 1073 - 1075. [Full Text] [PDF] |
||||
![]() |
Y. Bottcher, A. Korner, T. Reinehr, B. Enigk, W. Kiess, M. Stumvoll, and P. Kovacs ENPP1 Variants and Haplotypes Predispose to Early Onset Obesity and Impaired Glucose and Insulin Metabolism in German Obese Children J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4948 - 4952. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Rautanen, J. G. Eriksson, J. Kere, S. Andersson, C. Osmond, P. Tienari, H. Sairanen, D. J. P. Barker, D. I. W. Phillips, T. Forsen, et al. Associations of Body Size at Birth with Late-Life Cortisol Concentrations and Glucose Tolerance Are Modified by Haplotypes of the Glucocorticoid Receptor Gene J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4544 - 4551. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Freeman and R.D. Cox Type-2 diabetes: a cocktail of genetic discovery Hum. Mol. Genet., October 15, 2006; 15(suppl_2): R202 - R209. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Bochenski, G. Placha, K. Wanic, M. Malecki, J. Sieradzki, J. H. Warram, and A. S. Krolewski New Polymorphism of ENPP1 (PC-1) Is Associated With Increased Risk of Type 2 Diabetes Among Obese Individuals Diabetes, September 1, 2006; 55(9): 2626 - 2630. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. de Rooij, R. C. Painter, D. I.W. Phillips, C. Osmond, M. W.T. Tanck, J. C. Defesche, P. M.M. Bossuyt, R. P.J. Michels, O. P. Bleker, and T. J. Roseboom The Effects of the Pro12Ala Polymorphism of the Peroxisome Proliferator-Activated Receptor-{gamma}2 Gene on Glucose/Insulin Metabolism Interact With Prenatal Exposure to Famine Diabetes Care, May 1, 2006; 29(5): 1052 - 1057. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Bacci, O. Ludovico, S. Prudente, Y.-Y. Zhang, R. Di Paola, D. Mangiacotti, A. Rauseo, D. Nolan, J. Duffy, G. Fini, et al. The K121Q Polymorphism of the ENPP1/PC-1 Gene Is Associated With Insulin Resistance/Atherogenic Phenotypes, Including Earlier Onset of Type 2 Diabetes and Myocardial Infarction Diabetes, October 1, 2005; 54(10): 3021 - 3025. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Abate, M. Chandalia, P. Satija, B. Adams-Huet, S. M. Grundy, S. Sandeep, V. Radha, R. Deepa, and V. Mohan ENPP1/PC-1 K121Q Polymorphism and Genetic Susceptibility to Type 2 Diabetes Diabetes, April 1, 2005; 54(4): 1207 - 1213. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |